AL型淀粉样变性的分子全景
本文综述AL型淀粉样变性的分子全景,聚焦遗传学、转录组学和蛋白质组学改变,包括染色体异常、体细胞突变、基因表达异常、蛋白折叠通路紊乱及细胞因子和趋化因子分泌的作用。这些因素共同驱动致病性轻链的过量产生和不稳定,导致器官特异性淀粉样沉积、临床异质性和患者结局差异。综述强调整合DNA、RNA和蛋白质水平分析对深化发病机制理解、改进诊断预后和治疗策略的重要性。
要点
- 染色体异常、体细胞突变和基因表达异常共同驱动致病性轻链过量产生。
- 蛋白折叠通路紊乱及细胞因子和趋化因子分泌参与AL型淀粉样变性发病。
- 整合DNA、RNA和蛋白质水平分析有助于推进AL型淀粉样变性的精准医学。
核心结论
- AL型淀粉样变性分子机制复杂,需整合DNA、RNA和蛋白质水平分析以深化对发病机制的理解,从而改进诊断、预后和治疗策略并推进精准医学。
- 尽管治疗取得进展,该病的复杂性仍对开发生物模型构成挑战,迈向个体化治疗需要开发临床前模型并识别生物标志物和分子数据以设计靶向干预。
研究设计与样本
- 本文为综述,探讨AL型淀粉样变性的分子全景,强调遗传学、转录组学和蛋白质组学改变。
主要发现
- 关键发现包括染色体异常、体细胞突变、异常基因表达、蛋白质折叠通路紊乱以及细胞因子和趋化因子分泌的作用。
- 这些因素共同驱动致病性轻链的过量产生和不稳定,导致器官特异性淀粉样沉积、临床异质性和患者结局差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Amyloid light-chain (AL) amyloidosis is a systemic clonal plasma cell disorder characterized by the production and deposition of misfolded immunoglobulin light chains (LCs), resulting in multiorgan dysfunction. Due to its intricate molecular mechanisms and diverse organ involvement, the disease poses significant diagnostic and therapeutic challenges. This review explores the molecular landscape of AL amyloidosis, emphasizing genetic, transcriptomic and proteomic alterations. Key findings include chromosomal abnormalities, somatic mutations, aberrant gene expression, disrupted protein folding pathways and the role of cytokine and chemokine secretion. These factors collectively drive the overproduction and destabilization of amyloidogenic LCs, leading to organ-specific amyloid deposition, clinical heterogeneity and variable patient outcomes. Despite therapeutic advancements, the disease's complexity challenges the development of effective biological models. Progressing towards personalized therapies requires the development of preclinical models and the identification of biomarkers and molecular data to design targeted interventions. This review highlights the importance of integrating DNA, RNA and protein-level analyses to deepen the understanding of AL amyloidosis pathogenesis. Such insights are pivotal for improving diagnostics, prognostics and therapeutic strategies, ultimately advancing precision medicine for this challenging disease.
引用
- Zvida-Bloch T, Muchtar E, Dispenzieri A, et al. The molecular landscape of AL amyloidosis. Br J Haematol. 2025. PMID: 40211787. doi:10.1111/bjh.20070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。